Omnicell

OMCL · NASDAQ

$36.49+$0.68 (+1.90%)TodayMarket closed ·
Prev close $35.81

About OMCL

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. The company is headquartered in Fort Worth, Texas and currently employs 3,580 full-time employees. The company went IPO on 2001-08-08. The firm is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. The company provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. The company provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.

Employees
3,580
Headquarters
Fort Worth, Texas
Listed
Aug 8, 2001
Sector
Health Care
Industry
Health Care Equipment & Supplies

OMCL key statistics

Market cap
1.63B
Price-earnings ratio
42.63
Dividend yield
—
Average volume
464.67K
Volume
444.72K
Open price
$36.10
High today
$36.80
Low today
$36.01
52 Week high
$55.00
52 Week low
$29.09

Omnicell (OMCL) at a glance

Omnicell (OMCL) last traded at $36.49, with a market cap of 1.63B and a price-to-earnings ratio of 42.63.

Today the stock has traded between $36.01 and $36.80. The current price is 1.3% above the day's low and 0.8% below its high.

Volume so far is 444.72K shares, in line with the average of 464.67K shares a day.

Over the past year Omnicell has ranged from $29.09 to $55.00, and now sits 29% of the way up that range.

Omnicell met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.94 per share against an estimate of $0.4769.

The average analyst price target is $59.01, 61.7% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 9 analystsAvg $59.01
Low
$45.45
Now
$36.49
High
$73.50

OMCL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 48.3% on average.

  1. Q3 FY24: reported $0.56 per share against an estimate of $0.413
  2. Q4 FY24: reported $0.60 per share against an estimate of $0.5916
  3. Q1 FY25: reported $0.26 per share against an estimate of $0.2091
  4. Q2 FY25: reported $0.45 per share against an estimate of $0.2669
  5. Q3 FY25: reported $0.40 per share against an estimate of $0.5062
  6. Q4 FY25: reported $0.40 per share against an estimate of $0.5062
  7. Q1 FY26: reported $0.55 per share against an estimate of $0.3379
  8. Q2 FY26: reported $0.94 per share against an estimate of $0.4769

OMCL news

  • Press releaseBusiness Wire

    Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026

  • Press releasePRNewswire

    TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

  • Press releaseBusiness Wire

    Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

  • Press releaseBusiness Wire

    EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination

  • Press releaseBusiness Wire

    Omnicell Announces Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

  • Press releaseBusiness Wire

    Nnamdi Njoku Appointed President of Omnicell

  • Press releaseBusiness Wire

    Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

Similar companies

Companies in the same industry as Omnicell

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.